Fig. 1
Therapeutic effects of Oncolytic simplex virus type I and II in a CT26 model. Balb/c mice were subcutaneously implanted with CT26 tumor cells and intratumorally injected with oHSV1-GM-CSF and oHSV2-GM-CSF (n = 5–6 per group). A Schematic representation of the CT26 tumor-bearing mice model treated with the OVs on days 0, 3, 6. B Tumor volumes growth curves of the low dose (1 × 104 CCID50) and mock-treated groups, and data are presented as the mean + SD. C The tumor volumes on day 30 of the mice from the control and OVs treated groups in (B). *P < 0.05 by unpaired Student’s t-test. D Tumor volumes growth curves of treatment-naive and mice cured with the low dose treatment rechallenged by subcutaneous injection of CT26 cells. n = 2 for oHSV2-GM-CSF cured group, n = 4 for treatment-naive group. E Tumor volumes growth curves of the high dose (1 × 106 CCID50) and mock-treated groups, data are shown as mean + SD. F The tumor volumes on day 10 of the mice from the control and OVs treated groups in (D). G Tumor volumes growth curves of treatment-naive and mice cured with the high dose treatment rechallenged by subcutaneous injection of CT26 cells. n = 6 for oHSV2-GM-CSF cured group, n = 6 for oHSV1-GM-CSF cured group, and n = 4 for treatment-naive group